Artificial Pancreas Device System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The artificial pancreas device system market size is expected to grow from USD 1.01 billion in 2025 to USD 1.19 billion in 2026 and is forecast to reach USD 2.72 billion by 2031 at 17.94% CAGR over 2026-2031. This report is Segmented by Device Type (Threshold Suspended Device System, Control-To-Range (CTR) System, Control-To-Target / Hybrid Closed-Loop System, and Fully Automated Closed-Loop / Bionic Pancreas), End User (Hospitals & Clinics and More), Patient Age Group (Pediatric and Adult), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Artificial Pancreas Device System Market Trends and Insights

Escalating Global Incidence of Insulin-Dependent Diabetes Requiring Automated Glycemic Control

Diabetes affects 422 million people worldwide and could reach 629 million by 2045, heightening demand for technology that eases daily insulin management. Healthcare systems seek cost-effective methods to curb complications, and artificial pancreas platforms improve time in target glucose range by 12.59% versus conventional pumps, lowering hospitalization risk. Insurers increasingly classify these systems as long-term cost savers despite high upfront prices, facilitating uptake across high-income markets and gradually in price-sensitive regions.

Accuracy & Wearability Advances in Continuous Glucose Monitoring Sensors

Smaller, more precise CGM sensors such as Dexcom G7 and Abbott’s dual-analyte devices extend wear duration and reduce calibration needs, strengthening the value proposition of artificial pancreas solutions. FDA approval of over-the-counter CGM in 2024 broadened access, while longer-wear sensors like Eversense 365 support a full-year implant cycle. Improved comfort and reliability drive higher patient adherence, directly boosting automated insulin delivery performance.

High Total Cost of Ownership and Patchy Insurance Coverage in Emerging Economies

Acquisition costs can exceed USD 7,000, with annual consumables adding thousands more, challenging affordability where reimbursement is limited. Payer decisions vary by clinical evidence and budget impact, resulting in unequal access between insured and uninsured groups. In middle-income countries, public insurance rarely covers advanced diabetes tech, slowing artificial pancreas adoption despite large patient pools.

Other drivers and restraints analyzed in the detailed report include:

• Shift Toward Home-Based, Connected Chronic Care Driving Adoption of Wearable AID Devices
• Med-Tech-Digital Health Convergence Enabling Integrated Artificial Pancreas Ecosystems
• Cyber-Security, Data Privacy & Interoperability Risks in Connected AID Platforms

Segment Analysis

Hybrid closed-loop platforms generated 46.78% of 2025 revenue, serving as a transitional step toward full automation while preserving manual bolus discretion. They command much of today’s artificial pancreas device system market owing to clinician familiarity and incremental cost over legacy pumps. Fully automated/bionic solutions are projected to grow at 23.85% CAGR, fueled by AI-driven dual-hormone algorithms that deliver an 80% average time-in-range and markedly reduce hypoglycemia. Threshold-suspend and control-to-range models retain niche roles for users prioritizing simplicity or cost, but their share will decline as algorithmic sophistication becomes mainstream.

Second-generation bionic pancreases leverage neural-network-based pattern recognition to auto-adjust basal and bolus doses based on sensed metabolic trends, removing the need for carb counting in many scenarios. Manufacturers pair these systems with interoperable CGM to attract do-it-yourself (DIY) communities transitioning toward regulated products. Regulatory bodies now provide modular clearances for pumps and sensors, encouraging competitive mix-and-match ecosystems that expand patient choice within the artificial pancreas device system market.

Insulin pumps represented 49.92% of 2025 component revenue and remain foundational to every deployment. Miniaturized tubeless formats such as Tandem Mobi enhance discretion, while smartphone-controlled models like Medtronic’s MiniMed 8-Series streamline daily routines. Algorithms/software exhibit the fastest 25.14% CAGR because deep-reinforcement learning enables highly personalized insulin titration, boosting median time-in-range to 87.45%. This growth underpins expanding demand for upgradable firmware licenses, a recurring-revenue layer inside the artificial pancreas device system market.

CGM sensors form the second-largest value pool, and upgrades to one-year implants reduce service burden. Disposable sets and sensor consumables provide steady annuity streams for manufacturers. Component-level interoperability designations from the FDA accelerate multi-vendor pairing, positioning software innovators to capture value without owning hardware.

Complete Report Scope:

• By Device Type
  • Threshold Suspend Device System
  • Control-to-Range (CTR) System
  • Control-to-Target / Hybrid Closed-Loop System
  • Fully Automated Closed-Loop / Bionic Pancreas
• By Component
  • Insulin Pump
  • Continuous Glucose Monitor
  • Control Algorithm / Software
  • Disposable Infusion Sets & Sensors
• By End User
  • Hospitals & Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
• By Patient Age Group
  • Pediatric (Less Than 18 Years)
  • Adult (Greater Than 18 Years)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 42.98% revenue in 2025, leveraging high type 1 diabetes prevalence, broad private insurance coverage for AID, and an active VC ecosystem. FDA approval of over-the-counter CGM broadened candidate pools and lowered entry hurdles. Beta Bionics’ USD 206 million IPO in 2025 exemplified investor conviction and funded U.S. commercial scale-up.

Europe ranks second by revenue, backed by robust universal healthcare and supportive clinical guidelines. The U.K.’s National Health Service began national rollout of artificial pancreases in 2024, setting a cost-effectiveness precedent for other public payers. Data-privacy regulation spurs manufacturers to implement advanced cybersecurity, potentially offering European patients higher trust in connected ecosystems.

Asia-Pacific is the fastest-growing region at 18.88% CAGR through 2031. Urbanizing lifestyles have lifted regional diabetes incidence, and rising household income supports uptake of premium devices. China and India house large patient pools; tiered pricing and local manufacturing alliances help mitigate affordability constraints. Japan’s aging demographics and favorable reimbursement drive high per-capita device density. Regional digital-health infrastructure allows smartphone-centric artificial pancreas deployments to integrate seamlessly with national telemedicine platforms, propelling further expansion.

List of Companies Covered in this Report:

• Medtronic
• Tandem Diabetes Care
• Insulet
• Dexcom
• Beta Bionics Inc.
• Abbott Laboratories
• Bigfoot Biomedical Inc.
• Johnson & Johnson (Animas legacy)
• Roche
• Ypsomed
• Admetsys
• Pancreum Inc.
• Defymed
• Eli Lilly and Company
• MicroTech Medical Co. Ltd.
• SOOIL Development
• DreaMed Diabetes

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support